Wednesday, 13 February 2019

Ophthalmic Drugs Market to show steady growth, 2018

Market Scenario
Owing to the rising cases of eye diseases, the demand for an effective treatment option has also been escalating. In the recent years, various new and existing marketers have come up with effective drugs. For instance, in November 2017, Bausch & Lomb, a U.S.-based company, received the FDA approval for Vyzulta (latanoprostene bunod ophthalmic solution). The drug is designed for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension.
A number of factors such as rising prevalence of eye diseases, growing awareness, huge research funding in ophthalmology, unmet medical needs, rising competition among market players, improving regulatory framework, aging population, and increasing government assistance, are a few factors propelling the growth of the global ophthalmic drugs market. According to the 2017 statistics suggested by the World Health Organization (WHO), the chronic eye disease is the main cause of vision loss, globally.
However, the high cost associated with a diagnosis of eye diseases, side effects of available treatment options, and lack of healthcare insurance may hamper the growth of the market.
It is estimated that the ophthalmic drugs market is expected to grow at a CAGR 6.0% during the forecast period of 2017 to 2023.
Key Players
Some of the key players in the global ophthalmic drugs market are Actavis Generics, Allergan Plc, Bausch & Lomb Inc., Genentech, Inc., Merck & Co., Inc., Pfizer Inc., Regeneron Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., Shire Plc, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., Valeant Pharmaceuticals International, Inc., and others.
Regional Analysis
The Americas dominates the ophthalmic drugs market owing to the presence of patient population, rising prevalence of eye diseases, well-developed technology, high healthcare expenditure, and the presence of the leading players. According to the glaucoma research foundation, in the United States, more than 120,000 are blind because of glaucoma. This accounts for 9 to 12% of all the cases of blindness. It is also reported that over 3 million Americans have glaucoma, but only a few of them know they have it. It is also reported that glaucoma accounts for more than 10 million visits to physicians each year. In November 2017, Bausch & Lomb, a U.S.-based company, received the FDA approval for Vyzulta (latanoprostene bunod ophthalmic solution). The drug is designed for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension. In December 2017, Rhopressa (netarsudil ophthalmic solution) by Aerie Pharmaceuticals has also received the FDA approval for the treatment of glaucoma or ocular hypertension.
Europe holds the second position in the ophthalmic drugs market. It is expected that the government support towards research and development expenditure, increasing competition among marketers, and amendments in reimbursement policies in healthcare are likely to drive the European market.
Asia Pacific is the fastest growing ophthalmic drugs market owing to a huge patient pool, increasing demand, and development in healthcare technology.
The Middle East and Africa hold the lowest share of the global ophthalmic drugs market due to low development, lack of technical knowledge, and poor medical facilities.
Segmentation
The global ophthalmic drugs market is segmented on the basis of indication, drug class, type of dosage, product, distribution channel.
On the basis of indication, the market is classified as glaucoma, retinal disorders, inflammation/infection, dry eye, allergies, uveitis, and others.
On the basis of the drug class, the market is classified as antiallergy, anti-VEGF agents, anti-inflammatory, antiglaucoma, and others. The anti-inflammatory class is further segmented into nonsteroidal drugs and steroidal drugs.
On the basis of type of dosage, the market is classified as eye drops, eye solutions, ointments, capsules and tablets, and gels.
On the basis of the product, the market is classified as prescription drugs and OTC drugs.
On the basis of the distribution channel, the market is classified as hospital pharmacies, online pharmacies, drug stores, and others.
Browse Complete 85 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/ophthalmic-drugs-market-5753

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Pharmaceutical Analytical Testing Outsourcing Market to Observe Significant Growth by 2018

Market scenario
Global pharmaceutical analytical testing outsourcing market is expected to grow significantly over the forecast period. It is anticipated that the market held a valuation of USD 5080 million in 2017 and is projected to grow at a CAGR of 7.45% over the forecast period.
Analytical testing is one of the critical elements in the drug development process. In the pharmaceutical analysis, analytical assay methods are included in the compendial monographs with the aim to characterize the quality of bulk drug materials by setting limits of their active ingredient content.
Intense competition among pharmaceutical companies has placed pressure on analytical testing providers to generate quality results. Analytical testing helps in improving productivity, characterize biologics and biosimilars, optimize and monitor processes and provide real-time product quality control. One of the most prominent reasons companies outsource analytical testing services is to access expertise, experience and expensive analytical equipment not available in-house.
Various other factors such as increasing research and development investments, increasing awareness about product quality, and safety and changing regulations for in vivo and in vitro tests are also expected to propel the growth of the market.
However, lack of awareness, and quality approvals and regulatory audits conducted in outsourcing laboratories can hinder the market growth over the forecast period.
Segmentation
The Global pharmaceutical analytical testing outsourcing market is segmented based on product type, services, end user and region.
The Global market for pharmaceutical analytical testing outsourcing, by product type is segmented into raw materials, finished products and active pharmaceutical ingredients.
The market, by services, is segmented into bioanalytical testing, method development & validation, stability testing, and others. The bioanalytical testing segment is further classified as clinical and non-clinical. The method development & validation segment is further classified as extractable & leachable, impurity method, technical consulting and others. The stability testing is further classified as drug substance, stability indicating method validation, accelerated stability testing, photostability testing and others.
Based on end user, the market is segmented into pharmaceutical and biopharmaceutical companies, contract research organizations and others.
In the current scope of the study, the above-mentioned segments are covered into the four global regions, namely the Americas, Europe, Asia-Pacific and the Middle East & African region.
The pharmaceutical analytical testing outsourcing market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European pharmaceutical analytical testing outsourcing market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.  The pharmaceutical analytical testing outsourcing market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The pharmaceutical analytical testing outsourcing market in the Middle East & Africa has been segmented into the Middle East and Africa.
Regional Market Summary
The Americas dominated the global market for pharmaceutical analytical testing outsourcing owing to presence of major market players and developed economies like US and Canada within the region. In 2018, Pharmaceutical Product Development, LLC expanded its GMP-compliant, analytical laboratory in Middleton, Wisconsin, USA. The new 32,000-square-foot lab, complements the company’s existing biologics capacity and was constructed for the stability and quality control testing of large-molecule drug products.
In 2017, it was estimated that Europe stood second in the global pharmaceutical analytical testing outsourcing market. This can be attributed to the rising research and development investments. For instance, in 2018, Almac Group announced that it will invest USD 493,000 in additional nuclear magnetic resonance instrumentation at its headquarters in Craigavon, UK.
Asia Pacific was projected to be the fastest growing region in 2017. Factors such as growing healthcare sector, increasing penetration of the market players within the region, and increasing government’s support for foreign investments drives the regional markets of the Asia Pacific region.
On the other hand, the Middle East and Africa held least share in the global pharmaceutical analytical testing outsourcing market due to the low per capita income, especially within the African region.
Key players
Some of the key players in the global Pharmaceutical Analytical Testing Outsourcing market are SGS SA, Toxikon, Inc, Eurofins Scientific, Pace Analytical Services LLC, Intertek Group plc, Pharmaceutical Product Development, LLC, Exova Group plc, Boston Analytical, Charles River Laboratories International, Inc, West Pharmaceutical Services, Merck KGaA, WuXi AppTec, Source BioScience and others.
Browse Complete 90 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/pharmaceutical-analytical-testing-outsourcing-market-7188
         
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Surgical Equipment Market Dynamics, Forecast, Analysis and Supply Demand 2018

Market Scenario
Surgical equipment are used for both minor and major surgical procedures in hospitals and surgical centers and have a wide range of application in neurosurgery, ophthalmic surgery, wound closure, urology, cardiovascular surgeries, orthopedic surgery, and others. Electrosurgical devices, surgical sutures and staples, handheld instruments, electrosurgical generators, and monitoring devices are the various equipment that are used in surgeries.
The global surgical equipment market is driven by the increasing prevalence of chronic diseases such as cardiovascular diseases, obesity, skin diseases, increasing number of surgeries in ambulatory surgical centers and hospitals, and rising geriatric population. Additionally, the growth of the medical device market, increasing number of surgical centers, and government initiatives have a synergistic effect on the market. However, the growth of the market is restrained by various factors such as high cost of surgical devices and strict regulatory policies for various regulatory authorities.
The global surgical equipment market is expected to grow at a CAGR of 6.2% during the forecast period.
Key Players
The key players in the global surgical equipment market include B. Braun Melsungen AG (Germany), CONMED Corporation (USA), COVIDIEN (USA), Erbe Elektromedizin GmbH (Germany), Ethicon USA, LLC. (USA), Integra LifeSciences Corporation (USA), KARL STORZ & Co. (USA), KLS Martin (Germany) MEDICON (USA), Smith & Nephew (UK), and Stryker Corporation (USA).
Segmentation
The global surgical equipment market is divided into product type, application, and end-user.
On the basis of product type, the market is segmented into surgical sutures and staplers, handheld instruments, electrosurgical devices, electrosurgical generators, monitoring devices, and others. Surgical sutures and staplers are further segmented into absorbable and non-absorbable sutures. Handheld instruments are sub-segmented into forceps, sutures, visual scope, and others. Electrosurgical devices are further categorized into electrosurgical instruments such as HET bipolar system, electrosurgical pencils, smoke evacuation system, electrosurgical generators, and others.
On the basis of application, the market is segmented into neurosurgery, wound closure, urology, cardiovascular surgeries, orthopedic surgery, and others.
On the basis of end-user, the market is segmented into hospitals, ambulatory surgical centers, and others.
Regional Analysis
Americas holds the largest share of the surgical equipment market. The growth of the medical device sector, increasing emphasis on quality care, and the availability of technologically-advanced surgical devices are the major drivers for the growth of the market. North America holds the largest share, with the U.S. being the largest contributor to the growth of the market. In the U.S., the presence of key players in the medical device industry and extensive use of surgical devices drive the market. South America also exhibits tremendous growth opportunities with an increase in the demand for surgical devices. The Agency for Healthcare Research and Quality reported that nearly 11 million and 10 million invasive and therapeutic surgeries were carried out in ambulatory and inpatient settings, respectively, in the U.S. in 2014.
Europe, Germany, the U.K., and France are the major contributors to the growth of the market. The increasing number of market players manufacturing surgical equipment, growing government support, and increase in outpatient surgeries drive the market in the European nations. Additionally, increasing healthcare spending by European nations such as the U.K. and Germany also contributes to the growth of the market.
The Asia Pacific, surgical equipment market, is driven by the huge demand for surgical devices and instruments, increasing awareness about quality care in hospitals and surgical centers, and the ever-increasing prevalence of chronic diseases such as cardiovascular diseases. India and Australia exhibit the fastest growth in the market owing to the availability of qualified and skilled medical professionals and growing healthcare expenditure.
In the Middle East and Africa, the market growth is attributed to the increasing availability of specialty care services in countries such as the United Arab Emirates and Saudi Arabia. Africa exhibits a steady growth with the demand for primary care services in the region.
Latest Industry News
  • Surgical services at the Georgetown Public Hospital have received a donation of medical equipment and supplies from the government of China. 28 DEC 2018
  • AppOrtho is utilizing the High Country’s first robot-assisted surgery system to aid with knee replacement surgeries. 3 JAN 2019
Browse Complete 130 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/surgical-equipment-market-556
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Pacemaker Market Growth and Restrain Factors Analysis By 2023

Market Scenario:
The global pacemaker market is likely to post a CAGR of 6.5% over the forecast period of 2018-2023, asserts Market Research Future (MRFR) in an exclusive study. Surging prevalence of cardiovascular diseases across the globe is the prime drive behind the growth of the global pacemaker market. A pacemaker is used in the management of atrial fibrillation, to maintain adequate heart rate. Increasing global geriatric remains a significant growth driver. The old age population is more prone to developing cardiac disorders and subsequently boosting the growth of the global pacemaker market. Technological advancements in the pacemaker arena have resulted in the development of improved pacemakers with extended battery life, smaller size, better performance, and reduced failure rate. Leadless pacemakers are the new addition to the pacemaker space. They are typically the size of a pill and can be implanted with a minimally invasive procedure. Other driving factors include raising awareness regarding cardiovascular disorders and the general decline in the prices of pacemakers and treatment procedures. The rise in a number of FDA approval for new pacemakers can also be credited for the growth of the market. On the contrary, the growth of the global pacemaker market might be hindered due to the high costs associated with pacemakers which limit market growth in price-sensitive markets. Post-implantation complications of pacemakers are also possible bottlenecks to the growth of the global pacemaker market.  The market growth is also at a threat from alternative treatment options.
Segmentation
The pacemaker market has been segmented based on product type, application, implant approach, and end user.
By product type, the global pacemaker market has been segmented into implantable, and external. The implantable segment has been segmented into single chamber, dual chamber, and biventricular.
By application, the global pacemaker market has been segmented into syncope, hypertrophic cardiomyopathy, bradycardia, and heart failure. The bradycardia segment has been further segmented into sinus node dysfunction and AV block.
By implant approach, the global pacemaker market has been segmented into endocardial approach and epicardial approach.
By end user, the global pacemaker market has been segmented into hospitals & clinics, ambulatory surgical centers, research & academic institutes, and others.
Regional Analysis
Geographically, the global pacemaker market has been segmented into the Americas, Europe, Asia Pacific (APAC), and the Middle East & Africa (MEA).
The Americas pacemaker market has been segmented into North America and South America. The Americas is at the forefront of the global pacemaker market due to the high prevalence of cardiovascular disorders in the region which induces greater demand for pacemakers. The region tends to adopt advanced technologies swiftly which coupled with higher affordability drives the market in the Americas.
Europe is the second largest market for a pacemaker. The Europe market is driven by government funding for R&D and the presence of leading market participants in the regions. APAC is slated to be the fastest growing market over the forecast period. The MEA market is likely to exhibit the lowest growth due to limited development in the medical field, lack of technical knowledge, and poor medical facilities.
Competitive Landscape
The key players in the global pacemaker market include Biotronik GmbH & Co. KG (Germany), Medtronic Plc (U.S.), Sorin Group, St. Jude Medical Inc. (U.S.), Edwards Lifesciences (U.S.), ATS Medical (U.S.), Vitatron Holding B.V. (the Netherlands), Zoll Medical Corporation (U.S.), and Boston Scientific Corporation (U.S.).
Industry Updates
December 2018- Carondelet St. Joseph’s Hospital in Tuscon, the US is now offering a leadless pacemaker which can be implanted through a minimally-invasive surgical procedure. The pacemaker can be used to treat patients with irregular or slower-than-normal heart rate. The new pacemaker is about the size of a vitamin pill and does not require cardiac wires.
Browse Complete 90 Pages Premium Research Report Enabled with 83 Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/pacemaker-market-1587
         
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Cardiac Monitoring and Cardiac Rhythm Management Device Market Anticipated To Witness Noteworthy Growth in the Coming Years

Market Scenario
Rising prevalence of cardiovascular diseases and the increasing number of unmet medical needs in undeveloped countries are leading to the growth of the cardiac monitoring and cardiac rhythm management device market. Technical advancements in drug-eluting, MRI compatible pacemakers, and Holter monitors are some of the factors leading to the growth of this market. The growth of the global cardiac monitoring device market is driven by the high prevalence of cardiovascular disorders worldwide. The increasing demand for minimally invasive surgeries drives the growth of this market. Advanced technologies in cardiac monitoring and cardiac rhythm management devices have also led to growth in this market.  However, factors such as stringent regulatory approval procedures, the high cost of cardiac devices, and lack of reimbursement policies in developing countries are hindering the growth of the market.
Global cardiac monitoring and cardiac rhythm management device market is expected to grow during the forecast period (2018 to 2023) at a CAGR ~4%.
However, the high cost of these devices in developing nations, preference of drugs over devices in the cardiac treatment, and limited insurance coverage options are some of the factors which are hampering the growth of the market.
Key Players
Some of the key players in the global cardiac monitoring and cardiac rhythm management device market are Abiomed, Berlin Hearth, Brotionik SE and Co. KG, Boston Scientific Corporation, Cardiac Science Corporation, General Electric(GE), Hill Rom Services Inc, Jarvik Hearth. Inc, Koninklijke Philips N.V, LivaNova plc, Medtronic plc, Nihon Kohden Corporation, ReliantHeart Inc, Schiller, and Abbott.
Segmentation
The global cardiac monitoring and cardiac rhythm management device market is segmented into types of cardiac devices, types of cardiac monitoring devices, types of cardiac rhythm management devices, and end-users. Further, the types of cardiac devices are segmented into pacemaker, biventricular pacemaker, implantable cardioverter defibrillator, and implantable cardiac loop recorder. Based on the types of cardiac monitoring devices the market is further segmented into electrocardiogram (ECG), Holter monitor, event monitor, implantable loop recorder, and cardiac output monitoring devices. Electrocardiogram (ECG) is further sub-segmented into telelectro-cardiogram, wireless ECG, and lead ECG test. Based on types of cardiac rhythm management devices, the market is segmented into defibrillators, pacemakers, and cardiac resynchronization therapy devices. Defibrillations are further sub-segmented into implantable defibrillators and external defibrillators. Based on end-user the market is segmented into hospitals, ambulatory surgical centers, and others.
Regional Market Summary
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The cardiac monitoring and cardiac rhythm management device market in the Americas has been further segmented into North America and South America, with the North American market divided into the US and Canada. The European cardiac monitoring and cardiac rhythm management device market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The cardiac monitoring and cardiac rhythm management device market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The cardiac monitoring device market in the Middle East and Africa has been segmented into the Middle East and Africa.
In terms of market value, North America will dominate the global cardiac monitoring and cardiac rhythm management device market during the forecast period. The increasing investment by North America in cardiac devices over the last few years has led to the growth of the market in this region. Increasing number of cardiac patients, better healthcare infrastructure, and advanced technology in cardiac monitoring equipment have boosted the cardiac monitoring and cardiac rhythm management device market in North America. The European market is expected to be the second-largest cardiac monitoring device market. The market growth in this region can be attributed to government funding and support of the healthcare sector coupled with increasing research and development. Moreover, a growing number of surgeries due to the changing lifestyle is contributing to the growth of the market in this region. Asia-Pacific is expected to be the fastest-growing cardiac monitoring device market during the forecast period owing to the increasing prevalence of cardiac diseases, rising investments in healthcare, increasing geriatric population, and expansions by market players in the region. Asia-Pacific is giving strong competition in the global cardiac monitoring device market by producing cost-effective products that are high in demand in local as well as global markets. The market in the Middle East and Africa is expected to account for the smallest share in the global cardiac monitoring device market due to the underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.
Browse Complete 85 Pages Premium Research Report Enabled with 79 Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/cardiac-monitoring-advance-technologies-global-market-6332

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Tuesday, 12 February 2019

Malaria Diagnostics Market Growth and Restrain Factors Analysis By 2023

The global malaria diagnostics market is expected to register a significant growth of 4.6 % CAGR during the forecast period (2018–2023)
Malaria is a serious life-threatening disease caused by a parasite, transmitted by the bite of infected anopheles mosquitoes. Infected mosquitoes transport the Plasmodium parasite. When the infected mosquito bites you, the parasite is released into your bloodstream. Once the human body becomes the host for the parasite it travels to the liver and matures. After some days, the mature parasite enters the bloodstream and starts to infect red blood cells (RBC). Humans suffering from malaria frequently experience fever, headache, weakness, vomiting
The improvements in technological advancements related to diagnostic tools with the growing demand for treatment in malaria-endemic countries is driving this market. Major factors driving the growth of the market are raising funds from the government, an increase in association between the industry and research centers. In the current years, there has been a renewed interest and commitment by the World Health Organization (WHO) to eradicate malaria in around 35 countries by 2030. World Health Organization (WHO) also estimated that by 2016, there would be 216 million clinical episodes and 445,000 deaths only due to malaria. The malaria diagnostic tests play a major role in recognizing the malarial cases and thus boosting the growth of malaria diagnosis market.
However, the dearth of appropriate monitoring standards at the country levels particularly in developing markets hinders the growth of the market. The weak regulatory framework and lack of awareness across the emerging nations is a prime concern for the manufacturers and healthcare providers. The absence of strong import export guidelines can lead to the use of substandard products that can lead to additional complications for patients. Besides, the long registration procedures, the market entry parameters must be assessed carefully for investment considerations.
Key Players
Some of the key players in the global malaria diagnostics market are Access Bio. Inc., Abbott Laboratories, Premier Medical Corporation Pvt. Ltd, Sysmex Partec GmbH, bioMérieux, Beckman Coulter Inc., Siemens Healthineers, Leica Microsystems GmbH, Nikon Corporation, Olympus Corporation, and Bio-Rad Laboratories Inc.
Segmentation
The global malaria diagnostics market has been segmented on the basis of technology and end-user.
On the basis of technology, the market has been classified as rapid diagnostic tests, microscopy, and molecular diagnostic tests. The molecular diagnostics tests are segmented into polymerase chain reaction (PCR) and real-time polymerase chain reaction (RT-PCR).
On the basis of end-users, the market has been classified as hospitals, clinics, community healthcare, and others.
On the basis of region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas has been further segmented into North America and South America, with the North American market divided into the US and Canada.
The European malaria diagnostics market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 
The malaria diagnostics market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The malaria diagnostics market in the Middle East and Africa has been segmented into the Middle East and Africa. 
Regional Market Summary
In the malaria diagnostics market, North America is anticipated to account for the largest market share due to the early adoption of advanced medical technologies, the rise in awareness, the rise in growth of the healthcare sector, and due to favorable compensation setting for many surgical procedures. In 2016, global governments of malaria-endemic countries have invested USD 2.7 billion in malaria control and elimination efforts. The US was the largest contributor by providing USD 1 billion for the eradication of malaria.
The European market is expected to hold the least share due to the growing number of malaria-free countries in the region.
The market share in Asia-Pacific is also projected to experience growth in the near future due to access to optimal treatment facilities and growing demand for advanced technology, better adoption rate, increase in disposable income, and rising medical tourism. The Asia-Pacific remains to be the second largest burden of malaria globally with 22 malaria-endemic countries accounting for roughly 28 million cases and 45,000 deaths every year. The WHO figures say that in the Asia-Pacific region, Myanmar, Pakistan, India, and Indonesia carry the highest malaria burden accounting for 89% of all malaria cases in the region.
The market in the Middle East and Africa is expected to account for the smallest share of the global malaria diagnostics market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities. Sub-Saharan Africa remains to bring an excessively high share of the global malaria burden on the Middle Eastern and African market. the region was home to 90% of malaria incidences and 92% of malaria deaths in 2015
Browse Complete 100 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/malaria-diagnostics-market-6432
         
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Breast Biopsy Market Growth and Restrain Factors Analysis By 2023

Market Scenario
Increased cancer detection rates globally have contributed to a rise in biopsy procedures. Market reports connected with the healthcare industry have been presented by Market Research Future which makes reports on other industry verticals that aims to analyze the current market scenarios better. The market is projected to develop at a favorable CAGR rate in the forecast period.
The prevalence of breast cancer has led to an increased level of reliance on breast biopsy procedures. Improved screening campaigns are also increasing the need for breast biopsy procedures. Furthermore, the rise in the awareness regarding cancer is anticipated to further motivate the expansion of the breast biopsy market in the forecast period.
Segmentation
The breast biopsy market has been carried out on the basis of guidance technology, technique type, product, and end-user. Based on product, the breast biopsy market has been segmented into biopsy tables, guidance systems, biopsy needles, biopsy wires, and others. The segmentation on the basis of technique type, the market is segmented into core needle biopsy, biopsy markers, fine needle aspiration biopsy, surgical biopsy, MRI-guided core needle biopsy, wire localization, and sentinel node biopsy. Additionally, the core needle biopsy segment is segmented into vacuum-assisted biopsy, ultrasound-guided core biopsy, stereotactic core needle biopsy, and freehand core-needle biopsy. The surgical biopsy is divided into excisional biopsy and incisional biopsy. Based on guidance technology, the breast biopsy market is segmented into mammography-guided magnetic resonance, CT-guided biopsy, ultrasound-guided, and other image-guided breast biopsy (thermography and PET). The end-user based segmentation of the market consists of ambulatory surgical centers, hospitals, diagnostic centers, among others. The regions that are a part of the breast biopsy market are Europe, Asia Pacific, Americas, and the Middle East and Africa.
Competitive Landscape
Significant reductions in administrative costs are inducing further expansion of the market. The vertical additions and product tactics of the market are boosting the potential of the market players. The development of a robust value chain is further motivating the development of the market. The strategic goals intended for the market are reinforced due to favorable product differentiation carried out by market competitors. The growth of the market is moving in a favorable direction due to new product launches or rising gross revenue of the players in the market. Increased adaptability of market players to new market trends and customers inclinations are lifting the growth curve of the market and will continue do so in the forecast period. The successful implementation of strategies is expected to motivate the market in the coming years.
The main players in the breast biopsy market globally are C.R. Bard Inc., NuVue Therapeutics, Argon Medical Devices, Inc., Devicor Medical Products Inc. Hologic Inc. Argon Medical Devices, Cook Medical Incorporated, Leica Biosystems, Encapsule Medical Devices LLC., Johnson & Johnson, Intact Medical Corporation, Becton, Dickinson and Company, Conceptus INC, Hologic Inc., Galini SRL, Karl Storz GmbH & Co. Kg, GE Healthcare.
Detailed Regional Analysis
The regional analysis of the breast biopsy market observes that the North American region is projected to account for the principal market share owing to the early implementation of sophisticated medical technologies and constant development by companies working in cancer diagnostics. The breast biopsy market is mainly focused on the North American and European regions, which is expected to account for more than 50% of the market portion. The European market is estimated to hold the next biggest market share as breast cancer is found to be most common in countries such as the UK and Belgium. The market share in the Asia Pacific region is also estimated to experience growth in the near future due to access to optimal treatment facilities, better adoption rate, growing demand for advanced technology, growing government initiatives, and rising healthcare costs. The market in the Middle Eastern and African region is projected to be responsible for the smallest share of the breast biopsy market owing to deficiency of technical knowledge, an underdeveloped healthcare sector, and meager medical facilities.
Browse Complete 100 Pages Premium Research Report Enabled with 90 Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/breast-biopsy-market-6288
         
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com